Genetic Variants of Annexin A2 and Cryptogenic Stroke (GENANXVA)

Centre Hospitalier Universitaire, Amiens

Status: Enrolling

Conditions: Fibrinolysis; Stroke; Genetic Variants of Host; Annexin A2

Treatments: Biological: blood withdrawal

Study type: Interventional

Funder types: Other

Identifiers

NCT06880107

PI2023_843_0150

Details and patient eligibility

About

Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke.

ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease.

Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.

Enrollment: 240 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
• Age from 18 years old

Exclusion criteria

• Transient ischemic attack
• Pregnancy

Trial design

Primary purpose: Screening

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

240 participants in 3 patient groups

cryptogenic stroke

Experimental group

Description:

cryptogenic stroke

Treatment:

Biological: blood withdrawal

ischemic stroke

Experimental group

Description:

ischemic stroke

Treatment:

Biological: blood withdrawal

control subjects

Active Comparator group

Description:

control subjects

Treatment:

Biological: blood withdrawal